Development of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus

Abstract Respiratory syncytial virus (RSV) is one of the main pathogens associated with lower respiratory tract infections in infants and young children worldwide. Exosomes secreted by antigen presenting cells (APCs) can elicit immune responses by carrying major histocompatibility complex (MHC) clas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Suyeon Hong, Shaobo Ruan, Zachary Greenberg, Mei He, Jodi L. McGill
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/84ecf41bbf6f4edc8615a68cd553ed8f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:84ecf41bbf6f4edc8615a68cd553ed8f
record_format	dspace
spelling	oai:doaj.org-article:84ecf41bbf6f4edc8615a68cd553ed8f2021-11-08T10:51:34ZDevelopment of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus10.1038/s41598-021-00765-x2045-2322https://doaj.org/article/84ecf41bbf6f4edc8615a68cd553ed8f2021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-00765-xhttps://doaj.org/toc/2045-2322Abstract Respiratory syncytial virus (RSV) is one of the main pathogens associated with lower respiratory tract infections in infants and young children worldwide. Exosomes secreted by antigen presenting cells (APCs) can elicit immune responses by carrying major histocompatibility complex (MHC) class I molecules complexed with antigenic peptides and other co-stimulating factors. Therefore, we developed novel immunomagnetic nanographene particles to sequentially isolate, surface engineer, and release intact dendritic cell (DC) exosomes for use as a potential vaccine platform against RSV. The H-2Db-restricted, immunodominant peptides from RSV (M187–195 and NS161–75) were introduced to MHC-I on DC-derived exosomes to express peptide/MHC-I (pMHC-I) complexes. A mouse model of RSV infection was used to define the immunogenicity of surface engineered exosomes for activating virus-specific immune responses. Ex vivo assays demonstrated that engineered exosomes carrying RSV-specific peptides can elicit interferon-gamma (IFN-γ) production by virus-specific CD8+ T cells isolated from RSV-infected C57BL/6 mice. In vivo assays demonstrated that subcutaneous administration of both M187–195 and NS161–75 engineered exosomes to mice, with or without additional adjuvant, appeared safe and well tolerated, however, did not prime antigen-specific CD8+ T cell responses. Surface engineered exosomes are immunogenic and promising for further development as a vaccine platform.Suyeon HongShaobo RuanZachary GreenbergMei HeJodi L. McGillNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Suyeon Hong Shaobo Ruan Zachary Greenberg Mei He Jodi L. McGill Development of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus
description	Abstract Respiratory syncytial virus (RSV) is one of the main pathogens associated with lower respiratory tract infections in infants and young children worldwide. Exosomes secreted by antigen presenting cells (APCs) can elicit immune responses by carrying major histocompatibility complex (MHC) class I molecules complexed with antigenic peptides and other co-stimulating factors. Therefore, we developed novel immunomagnetic nanographene particles to sequentially isolate, surface engineer, and release intact dendritic cell (DC) exosomes for use as a potential vaccine platform against RSV. The H-2Db-restricted, immunodominant peptides from RSV (M187–195 and NS161–75) were introduced to MHC-I on DC-derived exosomes to express peptide/MHC-I (pMHC-I) complexes. A mouse model of RSV infection was used to define the immunogenicity of surface engineered exosomes for activating virus-specific immune responses. Ex vivo assays demonstrated that engineered exosomes carrying RSV-specific peptides can elicit interferon-gamma (IFN-γ) production by virus-specific CD8+ T cells isolated from RSV-infected C57BL/6 mice. In vivo assays demonstrated that subcutaneous administration of both M187–195 and NS161–75 engineered exosomes to mice, with or without additional adjuvant, appeared safe and well tolerated, however, did not prime antigen-specific CD8+ T cell responses. Surface engineered exosomes are immunogenic and promising for further development as a vaccine platform.
format	article
author	Suyeon Hong Shaobo Ruan Zachary Greenberg Mei He Jodi L. McGill
author_facet	Suyeon Hong Shaobo Ruan Zachary Greenberg Mei He Jodi L. McGill
author_sort	Suyeon Hong
title	Development of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus
title_short	Development of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus
title_full	Development of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus
title_fullStr	Development of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus
title_full_unstemmed	Development of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus
title_sort	development of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/84ecf41bbf6f4edc8615a68cd553ed8f
work_keys_str_mv	AT suyeonhong developmentofsurfaceengineeredantigenicexosomesasvaccinesforrespiratorysyncytialvirus AT shaoboruan developmentofsurfaceengineeredantigenicexosomesasvaccinesforrespiratorysyncytialvirus AT zacharygreenberg developmentofsurfaceengineeredantigenicexosomesasvaccinesforrespiratorysyncytialvirus AT meihe developmentofsurfaceengineeredantigenicexosomesasvaccinesforrespiratorysyncytialvirus AT jodilmcgill developmentofsurfaceengineeredantigenicexosomesasvaccinesforrespiratorysyncytialvirus
_version_	1718442542118207488

Development of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus

Ejemplares similares